Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • From 1 edit to 6: Why avoiding double-strand DNA breaks matters in cell therapy engineering
immune engineering hero
Infographic

From 1 edit to 6: Why avoiding double-strand DNA breaks matters in cell therapy engineering

As cell therapies become more complex, scientists are having to reconsider their engineering approach to avoid increasing structural risk.

Inside this infographic:

  • The impact of double strand breaks (DBSs) for cell therapies
  • Data illustrating how the risks grow as you scale up
  • A comparison of editing approaches
  • The consequences of these approaches for manufacturing

Download your free copy now.

The Pin-point™ base editing platform technology is available for clinical or diagnostic study and commercialization under a commercial license from Revvity.

Download Resource

From 1 edit to 6: Why avoiding double-strand DNA breaks matters in cell therapy engineering

Download Infographic
Revvity Logo

©2026 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.